Maastricht, The Netherlands, 1 November 2017 — Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has
begun a Phase 1b...
2015 —
Began a Phase 1b clinical trial of two experimental Ebola vaccines in Kampala, Uganda, using Chimpanzee Adenovirus type 3 vector (ChAd3) vaccines, co-developed by the VRC, National Institutes of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKine.